✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

By the time you hit your mid-30s, your body’s natural growth hormone output has already started to decline — by around 14% per decade according to long-term endocrine research. That decline is linked to slower recovery, harder fat loss, lighter sleep, and the gradual changes in body composition most people associate with aging. The Ipamorelin and CJC-1295 stack is one of the most popular peptide protocols designed to gently nudge your own pituitary gland to produce more growth hormone — without the spikes and side effects of synthetic GH itself. This guide breaks down exactly what each peptide is, how the combination works, what the science actually shows, the realistic safety picture, dosing strategies, and how it compares with synthetic HGH and other recovery peptides. By the end you will know whether the Ipamorelin/CJC-1295 stack fits your goals — and how to use it intelligently.

Ipamorelin and CJC-1295: The Growth Hormone Peptide Stack for Recovery, Sleep & Body Composition

Last updated: April 7, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Are Ipamorelin and CJC-1295? (Definition & Background)

Ipamorelin and CJC-1295 are two complementary peptides that stimulate the pituitary gland to release more of the body’s own growth hormone. Ipamorelin is a selective ghrelin-receptor agonist (a “GHRP”) that triggers GH release, while CJC-1295 is a long-acting analog of growth hormone releasing hormone (GHRH) that amplifies that release. Used together, they create a synergistic GH boost that mimics the body’s natural pulsatile pattern.

Ipamorelin is a synthetic pentapeptide developed in the late 1990s by Novo Nordisk. It belongs to a class called growth hormone releasing peptides (GHRPs), which all activate the ghrelin receptor in the pituitary. What makes ipamorelin special is its selectivity: older GHRPs like GHRP-6 and hexarelin also raise cortisol, prolactin, and hunger. Ipamorelin produces a clean GH release with minimal off-target effects, which is why it has become the most popular GHRP in modern peptide therapy.

CJC-1295 is a modified version of growth hormone releasing hormone (GHRH), originally developed by ConjuChem in the early 2000s. It comes in two forms. CJC-1295 without DAC (also known as Mod GRF 1-29) has a short half-life of about 30 minutes — it produces a sharp, natural-looking GH pulse. CJC-1295 with DAC (Drug Affinity Complex) includes a chemical group that binds to serum albumin, extending its half-life to roughly 6–8 days and producing a steady “GH bleed” rather than a pulse.

Both peptides are research compounds and have not been approved by the FDA, EMA, or other major regulators for human use. Both are also on the World Anti-Doping Agency Prohibited List under section S2 — peptide hormones, growth factors, related substances. Anyone competing under WADA rules should avoid both regardless of formulation. For everyone else, the Ipamorelin/CJC-1295 stack remains one of the most popular peptide protocols in research and clinical wellness practice.

How Does the Ipamorelin/CJC-1295 Stack Work? (Mechanism & Science)

The reason Ipamorelin and CJC-1295 are almost always discussed together is that they work through two completely different receptors in the pituitary — and combining them produces more growth hormone release than either peptide can achieve alone. This is the central insight behind the stack.

Think of GH release as a car engine. CJC-1295 is the accelerator — it pushes the GHRH receptor to fire and tells the pituitary “release more GH.” Ipamorelin is the spark plug — it activates the ghrelin receptor and amplifies whatever signal the GHRH receptor is producing. Use either alone and you get a moderate effect. Use both together and the engine roars louder than either input would predict.

Ipamorelin: the GHRP signal

Ipamorelin binds to the ghrelin receptor (GHS-R1a) in the pituitary, mimicking the action of ghrelin (the “hunger hormone”). Activating this receptor stimulates GH release through a pathway separate from GHRH. Older GHRPs in this class also activate cortisol, prolactin, and ACTH pathways — which is why they cause hunger spikes and stress responses. Ipamorelin’s selectivity means it triggers GH release without those off-target effects.

CJC-1295: the GHRH amplifier

CJC-1295 mimics natural growth hormone releasing hormone, the body’s primary signal that tells the pituitary to release GH. It binds to the GHRH receptor and increases the size and duration of each GH pulse. The “without DAC” version produces a short, sharp pulse similar to what your body would do naturally. The “with DAC” version produces a much longer-lasting elevation because it binds to serum albumin and stays active for days.

The synergistic effect

Because Ipamorelin and CJC-1295 act on different receptors, their effects multiply rather than add. When given together, the combined GH release is substantially larger than either peptide alone — animal and early human work has shown 2–3x increases versus single-peptide dosing. Crucially, the GH release still respects the body’s natural negative feedback loops, so you do not get the runaway elevations and side effects associated with synthetic HGH.

Downstream effects on IGF-1

Most of growth hormone’s anabolic and recovery effects actually come from insulin-like growth factor 1 (IGF-1), which the liver produces in response to GH stimulation. By raising GH levels gently and pulsatilely, the Ipamorelin/CJC-1295 stack indirectly raises IGF-1, which is the molecule responsible for tissue repair, lean muscle preservation, and many of the body composition changes users report. This is why benefits typically take several weeks to become visible — the cascade has to play out.

The combined approach is also why this stack is considered safer and more sustainable than direct synthetic HGH use. Synthetic HGH overrides the body’s feedback system entirely. Ipamorelin and CJC-1295 work with the system, asking the pituitary to do more of what it already does naturally.

Key Uses & Applications of Ipamorelin and CJC-1295

The Ipamorelin and CJC-1295 stack is used for a defined set of goals tied directly to what growth hormone and IGF-1 do in the body. Most applications are off-label and not formally approved, but the underlying mechanisms are well understood and the user community is large enough to provide consistent feedback patterns.

1. Recovery and tissue repair

Higher GH and IGF-1 support faster recovery from training, surgery, and injury. The stack is particularly popular among active adults dealing with chronic overuse injuries, slower-than-expected post-workout recovery, or stalled rehabilitation. Users typically report better next-day soreness, improved sleep quality, and a faster sense of “bouncing back” between training sessions over a 6–12 week protocol.

2. Body composition: fat loss and lean mass

Growth hormone shifts the body toward lipolysis (fat burning) and protein synthesis. Many users on the Ipamorelin/CJC-1295 stack report gradual fat loss — particularly visceral fat — alongside maintenance or modest gains in lean muscle mass when paired with structured training and adequate protein. It is not a dramatic body recomposition tool on its own; it works best as a multiplier on top of solid diet and training.

3. Sleep quality and depth

Growth hormone is naturally released in pulses during deep (slow-wave) sleep. By stimulating an extra GH pulse around bedtime, the Ipamorelin/CJC-1295 stack often produces noticeably deeper, more restorative sleep within the first week or two. Many users say improved sleep is the first benefit they notice — often before any visible body composition or recovery changes.

4. Skin and connective tissue quality

GH and IGF-1 support collagen synthesis, skin thickness, and connective tissue strength. Users on longer protocols sometimes report better skin elasticity, improved nail quality, and faster healing of minor skin issues. This effect overlaps with what peptides like GHK-Cu (the copper peptide) do directly at the skin level — but through a different mechanism.

5. Anti-aging and general wellness

This is the most common reason people start the stack. The natural decline in GH production with age is linked to slower recovery, harder fat loss, and lighter sleep. The Ipamorelin/CJC-1295 stack is designed to gently restore some of that lost output, with the goal of supporting the kinds of physiological function people associate with their younger years. Realistic expectations matter — it is not a fountain of youth, but it can produce meaningful quality-of-life improvements over months.

6. Emerging and investigational uses

Researchers have explored growth hormone secretagogues for conditions including age-related muscle loss (sarcopenia), HIV-related wasting, and short bowel syndrome. Tesamorelin (a related GHRH analog) is FDA-approved for HIV-associated lipodystrophy. Ipamorelin and CJC-1295 themselves remain investigational and should not be used for diagnosed medical conditions outside qualified clinical supervision.

Ipamorelin and CJC-1295 Safety Profile, Side Effects & Dosage

The Ipamorelin/CJC-1295 stack has one of the cleaner side effect profiles in the peptide space, particularly compared to direct synthetic HGH use. Most reported side effects are mild, dose-related, and tend to fade as the body adapts. The biggest cautions are around metabolism (insulin sensitivity), water retention, and the same general safety principles that apply to any GH-stimulating compound.

Reported side effects

Most users tolerate the stack well. Side effects tend to be most noticeable during the first 1–2 weeks and after dose increases, then settle. The head rush after injection is the most consistently reported short-term effect and is harmless in healthy users.

Contraindications and important warnings

Ipamorelin and CJC-1295 should be avoided by anyone with active or recent cancer, since elevated GH and IGF-1 could in theory support tumor growth. They should also be avoided in pregnancy and breastfeeding, and used with caution in people with diabetes or insulin resistance because GH has counter-regulatory effects on insulin. People with serious cardiovascular disease, untreated thyroid disorders, or pituitary tumors should not use these peptides. Athletes subject to WADA rules must avoid both regardless of formulation.

General dosage guidance

Standard community protocols use 200–300 mcg of ipamorelin combined with 100–200 mcg of CJC-1295 without DAC per dose, given subcutaneously two to three times daily — typically pre-bed, on waking, and pre-workout. CJC-1295 with DAC is dosed once or twice per week at around 1–2 mg because of its long half-life. Cycles usually run 8–12 weeks followed by a break. These figures reflect community practice and research extrapolation, not validated clinical dosing. There is no FDA-approved dose, and anyone considering this stack should work with a knowledgeable clinician.

What Does the Research Say? (Evidence & Clinical Studies)

The clinical evidence base for Ipamorelin and CJC-1295 is unusual: stronger than most research peptides because both compounds reached human trials before development was discontinued, but still limited compared to FDA-approved medications. Reading the data carefully matters because most of it is from short-duration safety and pharmacokinetic studies rather than long-term efficacy trials.

Proven evidence (in short-term human trials)

Both ipamorelin and CJC-1295 have peer-reviewed human safety and pharmacokinetic data, which is unusual for compounds in this category. Studies confirm that ipamorelin produces selective GH release without significant cortisol or prolactin effects, and that CJC-1295 (especially the DAC version) raises GH and IGF-1 for extended periods when used at therapeutic doses. These are the foundational pharmacology findings that justify the stack.

Emerging evidence

Most longer-term efficacy data — fat loss, body composition, recovery, anti-aging — comes from related GHRH analogs like sermorelin and tesamorelin (the only FDA-approved compound in this class, indicated for HIV-related lipodystrophy). Findings on visceral fat reduction, lean mass preservation, and sleep quality from those compounds support the same mechanism behind the Ipamorelin/CJC-1295 stack, but extrapolating directly is not the same as having dedicated trials.

Anecdotal evidence

The user community for Ipamorelin and CJC-1295 is large and consistent in its reports: better sleep within 1–2 weeks, gradual recovery improvements over 4–6 weeks, modest body composition changes by 8–12 weeks, and skin and connective tissue benefits over longer protocols. These accounts cannot replace controlled trials, and selection bias is significant — but the consistency across thousands of user reports is itself a useful signal.

What we still do not know

We do not know the long-term safety of multi-year use of these peptides. We do not have head-to-head trials comparing the Ipamorelin/CJC-1295 stack to direct synthetic HGH for body composition or recovery outcomes. We also do not know how individual variation in pituitary function affects results. Research suggests the stack reliably elevates GH and IGF-1 in the short term, but the long-term picture is still being filled in.

Ipamorelin/CJC-1295 vs Alternatives — How Does It Compare?

The most useful comparisons are with synthetic HGH (the gold standard but with significant downsides), sermorelin (an older, FDA-approved GHRH analog with shorter action), and tesamorelin (the only FDA-approved GHRH analog still on the market, indicated for HIV-related lipodystrophy).

The Ipamorelin/CJC-1295 stack sits in an interesting middle ground: stronger GH release than sermorelin alone, much gentler than synthetic HGH, and notably cheaper than HGH protocols. For users who want measurable GH and IGF-1 elevation without the joint pain, water retention, and glucose problems associated with direct HGH use, the stack is often the more sensible choice. You can also browse our sermorelin product page if you want to compare directly with the older single-peptide approach, or look at tesamorelin specifications for the FDA-approved option in the same class.

Compared to recovery-focused peptides like BPC-157 and TB-500, the Ipamorelin/CJC-1295 stack works very differently. BPC-157 and TB-500 act directly on tissue repair mechanisms — angiogenesis, cell migration, collagen organization. The Ipamorelin/CJC-1295 stack works upstream by raising GH and IGF-1, which influence recovery indirectly across the whole body. For specific injuries, BPC-157 and TB-500 are usually faster. For long-term systemic recovery, body composition, and sleep, the GH stack tends to win.

How to Use Ipamorelin and CJC-1295 — Practical Guidance

Because both peptides are research compounds with no FDA approval, there is no official prescribing guide. The protocols below reflect how the stack is used in published research and by clinicians who work with peptide therapy off-label. Treat both peptides as serious compounds and not as casual supplements.

Step-by-step usage

1. Choose your CJC-1295 form. Most users start with CJC-1295 without DAC for natural pulsatile dosing. CJC-1295 with DAC is for users who want once- or twice-weekly injections and steady GH/IGF-1 elevation.
2. Reconstitute carefully. Both peptides are sold as lyophilized powder. Reconstitute with bacteriostatic water — add the water slowly down the side of the vial, then swirl gently. Do not shake.
3. Pick your protocol. The most common protocol is 200–300 mcg ipamorelin + 100–200 mcg CJC-1295 (no-DAC) per dose, two to three times daily. The most important dose is the one immediately before bed, to amplify your natural overnight GH pulse.
4. Inject subcutaneously. The abdomen is the most common injection site; rotate to avoid local irritation. Use insulin syringes for accuracy.
5. Time around food. Inject on an empty stomach if possible — high blood glucose or insulin can blunt GH release. Wait 20–30 minutes after injection before eating, especially before bed.
6. Be patient. Sleep changes appear within 1–2 weeks, recovery improvements within 4–6 weeks, and visible body composition changes typically by 8–12 weeks.
7. Cycle. Most protocols run 8–12 weeks on, then 4–8 weeks off. This helps preserve receptor sensitivity and avoid potential downregulation.

Forms available

Ipamorelin and CJC-1295 are sold as lyophilized (freeze-dried) powders in sterile vials for reconstitution and subcutaneous injection. Pre-mixed blends combining ipamorelin and CJC-1295 in a single vial are also common and reduce the number of injections. There is no oral form with meaningful bioavailability — the peptides are degraded by stomach acid.

Quality and sourcing tips

Peptide quality varies enormously between suppliers. Look for: third-party HPLC purity reports of ≥98%, mass spectrometry verification, sterile lyophilized vials with clear lot numbers, and proper cold-chain shipping. Avoid any source that cannot supply a current certificate of analysis. Browse our ipamorelin product page, CJC-1295 without DAC, or CJC-1295 with DAC for current specifications. The rest of our peptide guides library compares this stack with BPC-157, TB-500, and GHK-Cu in detail.

What to monitor while using the stack

Keep a simple log: dose, injection site, sleep quality, training recovery, body composition, and any side effects. Periodic blood work — fasting glucose, HbA1c, IGF-1 — is sensible if you are running the stack for more than a few months or at higher doses. Stop and consult a clinician if you notice persistent water retention, significant joint pain, numbness, or unexplained changes in blood sugar.

Frequently Asked Questions

Q: What is the difference between CJC-1295 with DAC and without DAC?
A: CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of about 30 minutes and produces sharp, pulsatile GH release similar to your natural pattern. CJC-1295 with DAC includes a chemical group that binds to serum albumin, extending its half-life to 6–8 days and producing a steady “GH bleed.” Most peptide-therapy protocols favor the no-DAC version because it more closely mimics natural GH pulsatility, while the DAC version is used when steady IGF-1 elevation is the goal.

Q: How long does it take Ipamorelin and CJC-1295 to work?
A: Most users notice deeper sleep within the first 1–2 weeks of consistent dosing. Recovery improvements typically appear within 4–6 weeks. Body composition changes — modest fat loss, slight lean mass preservation or gain — usually take 8–12 weeks to become visible. Skin, hair, and connective tissue benefits often take longer protocols to show. Patience matters: the stack works through a slow IGF-1 cascade rather than producing dramatic immediate effects.

Q: Are Ipamorelin and CJC-1295 banned in sports?
A: Yes. Both peptides are on the World Anti-Doping Agency Prohibited List under section S2 (peptide hormones, growth factors, related substances). They are prohibited in and out of competition. Any athlete subject to WADA-affiliated rules can be sanctioned for testing positive. If you compete at any level governed by anti-doping bodies, you should not use these peptides regardless of formulation. Always check the current WADA list before considering any new peptide.

Q: Can Ipamorelin and CJC-1295 cause cancer?
A: There is no direct evidence that either peptide causes cancer in humans. However, both raise growth hormone and IGF-1 levels, and elevated IGF-1 is theoretically concerning for tumor growth because some cancers depend on IGF-1 signaling. Anyone with active or recent cancer should avoid the stack unless cleared by an oncologist. People with no cancer history should still discuss the protocol with a clinician before starting, particularly if there are family risk factors.

Q: Can Ipamorelin and CJC-1295 build muscle?
A: They can support modest lean muscle gains, but the effect is gentle compared to anabolic steroids or direct synthetic HGH. The stack works by raising IGF-1, which supports protein synthesis and recovery. In practice, users on consistent protocols paired with structured training and adequate protein typically see modest body composition improvements over 8–12 weeks. The stack is best thought of as a long-term recovery and composition tool, not a rapid muscle-building shortcut.

Q: Should I take Ipamorelin and CJC-1295 before bed?
A: Yes — the pre-bed dose is the most important one. Growth hormone is naturally released in pulses during deep sleep, and stimulating an extra pulse around bedtime amplifies that natural rhythm. Inject 20–30 minutes before bed on an empty stomach for the strongest effect. Many users report deeper, more restorative sleep within the first week of the protocol, often before any other benefits become noticeable.

Q: Is the Ipamorelin/CJC-1295 stack safer than HGH?
A: For most users, yes. Synthetic HGH overrides the body’s natural feedback system entirely, producing supraphysiological GH levels and causing side effects like joint pain, water retention, carpal tunnel symptoms, and insulin resistance. The Ipamorelin/CJC-1295 stack works with the body’s pituitary, producing pulsatile GH release that respects natural feedback loops. Side effects are usually mild and self-limiting, and the safety margin is wider — though long-term human data on the stack itself remains limited.

Q: How do I store Ipamorelin and CJC-1295?
A: Lyophilized peptide is generally stable at room temperature for short periods but should be refrigerated for longer storage. Once reconstituted with bacteriostatic water, store both peptides at 2–8°C (refrigerator, not freezer) and use within 4–6 weeks. Avoid freezing reconstituted vials, protect from direct light, and check expiry dates. Properly stored peptides retain full activity; degraded peptide will not deliver expected results.

The Bottom Line — Is the Ipamorelin and CJC-1295 Stack Worth It?

The Ipamorelin and CJC-1295 stack is one of the most evidence-supported and well-tolerated peptide protocols available. By combining a selective ghrelin receptor agonist with a long-acting GHRH analog, it produces synergistic growth hormone release that respects the body’s natural pulsatile pattern. For adults dealing with declining recovery, lighter sleep, harder fat loss, and the broader signs of GH-axis aging, the stack offers a gentler, more sustainable alternative to direct synthetic HGH — at a fraction of the cost and with a much narrower side effect profile.

The honest caveat is the same as with all research peptides: long-term human evidence is limited, neither peptide is FDA-approved, and both are prohibited for competitive athletes. Results take time and depend on consistent dosing, proper injection timing, supporting nutrition and training, and realistic expectations. Anyone considering the protocol should treat it as a serious compound regimen, work with a knowledgeable clinician, and combine the peptides with a solid foundation of sleep, training, and diet.

If you fit the profile — an adult interested in evidence-based recovery, body composition, sleep, or anti-aging support — the Ipamorelin and CJC-1295 stack is worth a structured trial. Visit our ipamorelin product page, CJC-1295 without DAC, or CJC-1295 with DAC for current specifications, or browse our full library of peptide guides to compare this stack with BPC-157, TB-500, GHK-Cu, and other recovery options.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.